Metastatic melanoma: anti-ipilimumab antibodies tied to worse OS

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with metastatic melanoma treated with ipilimumab, low serum levels of ipilimumab and development of antidrug antibodies (ADAs) are associated with reduced survival.

Why this matters

  • Little is currently known about the clinical effects of ADA development.

Key results

  • Low serum levels of ipilimumab before the second infusion (n=24) were associated with reduced OS (HR, 1.3 per 1 μg/mL; P=.01) and PFS (HR, 1.2 per 1 μg/mL; P=.02).
  • Low serum levels of ipilimumab before the fourth infusion (n=20) were not significantly associated with OS or PFS (data not shown).
  • 26% of patients were ADA-positive at the second or fourth infusion.
  • ADA positivity was associated with reduced OS (HR, 3.0; P=.03).
  • 50% of ADA-positive patients vs 13% of ADA-negative patients discontinued therapy before the fourth infusion due to disease progression.
  • ADA positivity and lower serum levels of ipilimumab were not significantly associated (data not shown).

Study design

  • 31 patients with ipilimumab-treated metastatic melanoma were analyzed for drug serum levels, and ADAs to ipilimumab at baseline and the second and fourth infusions.
  • 77% received 4 infusions.
  • Primary endpoints were OS and PFS.
  • Funding: None disclosed.

Limitations

  • Small patient sample size.
  • Retrospective design.